Enhanced antitumor immune responses via a new agent [¹³¹I]-labeled dual-target immunosuppressant.

ABSTRACT: Radionuclides theranostic are ideal "partners" for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). An ionizing-radiation stimulus mediated by a low-dose of [¹³¹I] may be used for immunopotentiation. In this study, we established [¹³¹I]-labeled KN046 as a novel radioimmunotherapy agent to treat malignant melanoma and explored the mechanism.

Methods

After intravenous injection of [¹³¹I]-KN046, SPECT/CT imaging was applied to identify candidate targets for KN046 immunotherapy. [¹⁸F]-FDG and [

SUBMITTER: Jiang C 

PROVIDER: S-EPMC9816240 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature